Security key
869367102
Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (STRO)
CUSIP: 869367102
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 61,457,334
- Total 13F value
- $39,985,859
- Share change
- -1,410,222
- Put/Call ratio
- 185%
- SEC-reported price per share
- $0.65
- Number of holders
- 113
- Value change
- -$10,841,219
- Number of buys
- 55
- Number of sells
- 59
- Shares outstanding
- 16,607,375
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
113
Top holders
10
STRO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
SUTRO BIOPHARMA, INC. SEC filings
SUTRO BIOPHARMA, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 869367102
Recent filing periods:
Ownership snapshot
Top reported holders of STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
Lead comparable stake: 46%
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 46%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
46%
SUVRETTA CAPITAL MANAGEMENT, LLC
45%
VANGUARD GROUP INC
25%
Kynam Capital Management, LP
22%
Merck & Co., Inc.
16%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
Company
|
46%
|
$13,971,471
7,593,191 shares
|
— | 31 Dec 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
Company
|
45%
|
$13,730,991
7,462,495 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
25%
|
$7,743,639
4,208,500 shares
|
— | 31 Dec 2024 |
| Kynam Capital Management, LP |
13F
Company
|
22%
|
$6,700,262
3,641,447 shares
|
— | 31 Dec 2024 |
| Merck & Co., Inc. |
13F
Company
|
16%
|
$5,011,257
2,723,509 shares
|
— | 31 Dec 2024 |
| Vestal Point Capital, LP |
13F
Company
|
15%
|
$4,728,800
2,570,000 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
113
Shares
61,457,334
Rows available
113
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
122
Q1 2025 holders
113
Holder diff
-9
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend